Clinical trial
Predicting the Clinical Response to Omalizumab With Anti-Immunoglobulin E (IgE) Ab Response or Syk Expression in Basophils
NCT02023151
Study timeline
Study start (unknown)2013-02-01Date precision: month
Registry last updated2017-12-11
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Allergic Asthmaunresolved
Interventions
OmalizumabDRUG · verified · RxNorm: omalizumab
Sponsors & collaborators
Johns Hopkins Universitylead sponsor
Novartis Pharmaceuticalscollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT02023151 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.